echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CSPC's new anti-tumor nano drug was approved for clinical use

    CSPC's new anti-tumor nano drug was approved for clinical use

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 10, CSPC issued an announcement stating that the new anti-tumor nano-drug "Sirolimus for injection (albumin-binding)" developed by Sinoqi Pharmaceutical, a subsidiary of the company, had been approved for clinical trials in China
    .


    CSPC announced that this is the first injection-administered sirolimus preparation that has obtained a clinical trial license in China


    Sirolimus, also known as rapamycin, was originally developed by Pfizer
    .


    The drug is a macrolide antibiotic immunosuppressant, a specific inhibitor of mTOR, and is clinically used to prevent organ rejection in patients undergoing kidney transplantation


    It is reported that the clinical research indications approved for the drug this time are solid tumors and hematomas


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.